How do you administer Obinutuzumab?
Dilute 4 mL (100 mg) of GAZYVA into a 100 mL 0.9% sodium chloride infusion bag for immediate administration. Dilute the remaining 36 mL (900 mg) into a 250 mL 0.9% sodium chloride infusion bag at the same time for use on day 2 and store at 2°C to 8°C (36°F to 46°F) for up to 24 hours.
How long does Obinutuzumab infusion take?
Administer at 25 mg/hr over 4 hours. Do not increase the infusion rate. The Day 1 dose for GAZYVA is 100 mg in 100 mL.
What is the difference between Obinutuzumab and rituximab?
Obinutuzumab is a type II antibody, unlike rituximab, which is a type I antibody. These classifications are based on the way the antibodies bind to CD20.
What is the half life of Obinutuzumab?
Obinutuzumab has a volume of distribution of approximately 3.8 L, a total body clearance of 0.09 L/day, and an elimination half-life of approximately 28.4 days.
Is Obinutuzumab a chemotherapy drug?
Obinutuzumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. Obinutuzumab is classified as a “monoclonal antibody” (For more detail, see “How Obinutuzumab Works” section below).
What is half life of Obinutuzumab?
Is Obinutuzumab considered immunotherapy?
Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving bendamustine, obinutuzumab, and venetoclax may work better in treating patients with mantle cell lymphoma.
Does Obinutuzumab make you tired?
This treatment may cause difficulty sleeping. Some people may have depression or anxiety. If you notice these changes or any other changes to your mood, talk to your doctor or nurse.
Does Obinutuzumab cause shortness of breath?
Swelling of other parts of your body; Shortness of breath, wheezing or trouble breathing; Skin problems including rash, itchiness or hives, hardened or discoloured skin lesions which may increase in size.
How many times can you give obinutuzumab in a day?
DOSE TO BE ADMINISTERED DURING 6 TO 8 TREATMENT CYCLES, FOLLOWED BY OBINUTUZUMAB AS MONOTHERAPY FOR PATIENTS WITH FL: -Cycle 1, Day 1: 1000 mg IV at 50 mg/hr; the rate of infusion can be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr
When is obinutuzumab indicated in follicular lymphoma?
1) For patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen, administer obinutuzumab in combination with bendamustine in six 28-day cycles.
When should monotherapy of obinutuzumab (ibuprofen) be initiated?
During monotherapy, maintain the original dosing schedule for subsequent doses. Monotherapy should be initiated approximately 2 months after the last dose of obinutuzumab administered during the induction phase.
What type of antibody is obinutuzumab?
Obinutuzumab is a recombinant IgG1 monoclonal antibody that targets CD20 expressed on the surface of pre-B and mature B-lymphocytes. The drug promotes cell death via antibody-dependent cellular cytotoxicity and phagocytosis and via activation of the complement cascade.
